TScan Therapeutics Inc
TCRX
NASDAQ
Biotechnology
$0.78
USD
+0.01 (+0.88%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $50.45M
Volume 277.3K
Revenue
$7.11M
TTM
+2.2%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-117.71M
TTM
+13.9%
YoY
Operating Cash Flow
$-116.28M
TTM
+7.8%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 3.1 | 2.5 | 2.6 | 1.0 | 1.1 |
YoY Growth | +473.9% | +139.4% | +286.0% | -54.8% | -65.8% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 3.1 | 2.5 | 2.6 | 1.0 | 1.1 |
Selling, General & Administrative | 9.1 | 7.9 | 6.4 | 8.2 | 8.1 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 41.7 | 39.6 | 26.4 | 30.1 | 31.5 |
Operating Income | -38.7 | -37.1 | -23.9 | -29.1 | -30.5 |
EBITDA | -38.0 | -36.3 | -23.1 | -28.4 | -29.8 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 1.7 | 1.3 | 0.9 | 0.5 | 0.1 |
Income Before Income Taxes | -37.0 | -35.7 | -23.0 | -28.7 | -30.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -37.0 | -35.7 | -23.0 | -28.7 | -30.4 |
Consolidated Net Income / Loss | -37.0 | -35.7 | -23.0 | -28.7 | -30.4 |
Net Income Attributable to Common Shareholders | -37.0 | -35.7 | -23.0 | -28.7 | -30.4 |
Basic EPS | -$0.28 | -$0.28 | -$0.18 | -$0.22 | -$0.23 |
Diluted EPS | -$0.28 | -$0.28 | -$0.18 | -$0.22 | -$0.23 |
Basic Shares Outstanding | 129.7M | 129.8M | 129.9M | 129.9M | 129.9M |
Diluted Shares Outstanding | 129.7M | 129.8M | 129.9M | 129.9M | 129.9M |